Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > Be nice to c the new sites & patient enrollments
View:
Post by skyhawk1 on Mar 26, 2021 2:35pm

Be nice to c the new sites & patient enrollments

really SPEED UP especially in the USA?! I wonder what the HOLD UP is, especially since we have a non invasive PDT treatment with minimal or virtually no SIDE EFFECTS to speak of, that WORKS?!
 

Kinda strange & MYSTIFYING to understand the slow pace of PROGRESSION with our treatment?! It should be a 'SLAM DUNK' by now?!


The trading VOLUME sucks as well right now with all the POTENTIAL that TLT seems to offer INVESTORS?

 

BTW ~ no 'disrespect' to any true longs on here. BUT is everybody on here just sayin' that or r most posters on here ~ 80 years old or older?! 


Seen many boards on SH over the years, but can't recall any with as many seniors 80+ supposedly investing in a SPECULATIVE penny stock play?!
 

Strange INDEED?! G'day to any REAL LONGS!

Comment by biggerr on Mar 26, 2021 3:26pm
I agree, it's been a very slow pace so far - we'll be celebrating 3 years next month since the 2 patients got cured of their bladder cancer in the Phase I and since then no real progress. Hopefully things will speed up now with the 6th US site added, all they need is 9 more patients treated - how hard could that be, they could do it in one week for gawd sake
Comment by greaterfoolFred on Mar 26, 2021 3:45pm
I think we need to get real with the numbers.  FDA isn't going to let them leave the five with failed treatments out of the calculations like was done in the last quarterly report.  They will have to include all of the first 12 or none of them.  I think that our real 25 starts with patient 13, after the protocol was corrected.  So we really need 37.  C'est la vie ...more  
Comment by biggerr on Mar 26, 2021 4:01pm
I think their problem was in the adjustment of the laser because it turns out that you need to change the frequency and the wavelength of the laser beam in order to reach deeper tissue affected by the tumor. I think that took them all this extra time. Now that it's been hopefully fixed they can go at it again
Comment by 99942Apophis on Mar 26, 2021 4:38pm
Strictly my opinion, I feel all the adjustments in dosage and light will greatly improved the final CR percentages. I consider ourselves lucky in hindsight for what has occured in the beginning of this Ph2 study and as others have said it has now been fine tuned, my expectations is upward of 80+ . Gut feeling is we've got this one and I'm anxiously waiting for the announcement for GBM & ...more  
Comment by StevenBirch on Mar 26, 2021 8:01pm
Let's not forget Phase I was supposed to be 9 patients and was stopped early at 6 with questionable results on the first 4 because of unforseen circumstances! They really only had 3 treated with the therapeutic dose and corrections were made after P4 so only 2 were properly screened and fully treated. I know that was Phase I and was for safety but Phase II is setting up eerily similar in that ...more  
Comment by gebremeskel on Mar 27, 2021 10:58am
Seriously?
Comment by CancerSlayer on Mar 26, 2021 4:31pm
It will be interesting to see how the FDA approaches the protocol error.  Re the patients that were removed, the FDA should "not" consider them in the final analysis imo...data would be invalid & wouldn't reflect the true CR rate.  Though it would take longer, I agree the final analysis should only include data based on the corrected protocol.  We shall see...
Comment by floatinketucky on Mar 26, 2021 10:15pm
10 patients early 2021 for 25 for Breakthrough Designation Shawn Shirazi, PhD, Chief Executive Officer, Theralase®, stated, "Each CSS Theralase launches for Study II will aid in our objective of enrolling and treating 10 patients in early 2021 to achieve a total of 25 patients for potential Breakthrough Designation Approval and approximately 75 to 100 additional patients in 2021 / 2022 ...more  
Comment by skys1 on Mar 26, 2021 7:53pm
skyhawk1, The reason so many of us are old is because we have been in TLT for so many years. 9 years for me.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250